Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Pharmacokinetics of valerenic acid after single and multiple doses of valerian in older women.

Anderson GD, Elmer GW, Taibi DM, Vitiello MV, Kantor E, Kalhorn TF, Howald WN, Barsness S, Landis CA.

Phytother Res. 2010 Oct;24(10):1442-6. doi: 10.1002/ptr.3151.

PMID:
20878691
2.

A randomized clinical trial of valerian fails to improve self-reported, polysomnographic, and actigraphic sleep in older women with insomnia.

Taibi DM, Vitiello MV, Barsness S, Elmer GW, Anderson GD, Landis CA.

Sleep Med. 2009 Mar;10(3):319-28. doi: 10.1016/j.sleep.2008.02.001. Epub 2008 May 14.

3.

Potential interactions between complementary/alternative products and conventional medicines in a Medicare population.

Elmer GW, Lafferty WE, Tyree PT, Lind BK.

Ann Pharmacother. 2007 Oct;41(10):1617-24. Epub 2007 Sep 4.

4.

Echinacea alkylamides inhibit interleukin-2 production by Jurkat T cells.

Sasagawa M, Cech NB, Gray DE, Elmer GW, Wenner CA.

Int Immunopharmacol. 2006 Jul;6(7):1214-21. Epub 2006 Mar 7.

PMID:
16714226
5.

Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo.

Mohutsky MA, Anderson GD, Miller JW, Elmer GW.

Am J Ther. 2006 Jan-Feb;13(1):24-31.

PMID:
16428919
6.

Pharmacokinetics of valerenic acid after administration of valerian in healthy subjects.

Anderson GD, Elmer GW, Kantor ED, Templeton IE, Vitiello MV.

Phytother Res. 2005 Sep;19(9):801-3.

PMID:
16220575
7.

Drug interaction potential of soy extract and Panax ginseng.

Anderson GD, Rosito G, Mohustsy MA, Elmer GW.

J Clin Pharmacol. 2003 Jun;43(6):643-8.

PMID:
12817527
8.

Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease.

McFarland LV, Elmer GW, Surawicz CM.

Am J Gastroenterol. 2002 Jul;97(7):1769-75.

PMID:
12135033
9.

Update on natural product--drug interactions.

Scott GN, Elmer GW.

Am J Health Syst Pharm. 2002 Feb 15;59(4):339-47.

PMID:
11885397
10.

Does gastrointestinal Candida albicans prevent ubiquinone absorption?

Krone CA, Elmer GW, Ely JT, Fudenberg HH, Thoreson J.

Med Hypotheses. 2001 Nov;57(5):570-2.

PMID:
11735312
11.

Possible interaction between warfarin and Lycium barbarum L.

Lam AY, Elmer GW, Mohutsky MA.

Ann Pharmacother. 2001 Oct;35(10):1199-201.

PMID:
11675844
12.

Biotherapeutic agents in the treatment of infectious diarrhea.

Elmer GW, McFarland LV.

Gastroenterol Clin North Am. 2001 Sep;30(3):837-54. Review.

PMID:
11586560
13.

Probiotics: "living drugs".

Elmer GW.

Am J Health Syst Pharm. 2001 Jun 15;58(12):1101-9. Review.

PMID:
11449853
14.

The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii.

Surawicz CM, McFarland LV, Greenberg RN, Rubin M, Fekety R, Mulligan ME, Garcia RJ, Brandmarker S, Bowen K, Borjal D, Elmer GW.

Clin Infect Dis. 2000 Oct;31(4):1012-7. Epub 2000 Oct 25.

PMID:
11049785
15.

Antibiotics and Clostridium difficile diarrhea in the ambulatory care setting.

Levy DG, Stergachis A, McFarland LV, Van Vorst K, Graham DJ, Johnson ES, Park BJ, Shatin D, Clouse JC, Elmer GW.

Clin Ther. 2000 Jan;22(1):91-102.

PMID:
10688393
16.

Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients.

Elmer GW, McFarland LV, Surawicz CM, Danko L, Greenberg RN.

Aliment Pharmacol Ther. 1999 Dec;13(12):1663-8.

17.

Recurrent Clostridium difficile disease: epidemiology and clinical characteristics.

McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN.

Infect Control Hosp Epidemiol. 1999 Jan;20(1):43-50.

PMID:
9927265
18.
19.

Pharmaceutical probiotics for the treatment of anaerobic and other infections.

McFarland LV, Elmer GW.

Anaerobe. 1997 Apr-Jun;3(2-3):73-8.

PMID:
16887565
20.

Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial.

Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME.

Clin Infect Dis. 1997 Mar;24(3):324-33.

PMID:
9114180
21.
22.

Ciprofloxacin-associated Clostridium difficile disease.

McFarland LV, Bauwens JE, Melcher SA, Surawicz CM, Greenberg RN, Elmer GW.

Lancet. 1995 Oct 7;346(8980):977-8. No abstract available.

PMID:
7564771
23.

Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo.

McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL.

Am J Gastroenterol. 1995 Mar;90(3):439-48.

PMID:
7872284
24.

A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease.

McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL, Noorani Z, et al.

JAMA. 1994 Jun 22-29;271(24):1913-8. Erratum in: JAMA 1994 Aug 17;272(7):518.

PMID:
8201735
25.

Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers.

Klein SM, Elmer GW, McFarland LV, Surawicz CM, Levy RH.

Pharm Res. 1993 Nov;10(11):1615-9.

PMID:
8290474
27.

Influence of antibiotics on the recovery and kinetics of Saccharomyces boulardii in rats.

Boddy AV, Elmer GW, McFarland LV, Levy RH.

Pharm Res. 1991 Jun;8(6):796-800.

PMID:
2062812
29.

Prevention of further recurrences of Clostridium difficile colitis with Saccharomyces boulardii.

Kimmey MB, Elmer GW, Surawicz CM, McFarland LV.

Dig Dis Sci. 1990 Jul;35(7):897-901.

PMID:
2364845
30.
32.

Disposition kinetics of Saccharomyces boulardii in man and rat.

Blehaut H, Massot J, Elmer GW, Levy RH.

Biopharm Drug Dispos. 1989 Jul-Aug;10(4):353-64. No abstract available.

PMID:
2758101
33.
34.

Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study.

Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, van Belle G.

Gastroenterology. 1989 Apr;96(4):981-8.

PMID:
2494098
35.
36.

Role of the intestinal microflora in clonazepam metabolism in the rat.

Elmer GW, Remmel RP.

Xenobiotica. 1984 Nov;14(11):829-40.

PMID:
6506755
37.

Prevention of clindamycin-induced mortality in hamsters by Saccharomyces boulardii.

Toothaker RD, Elmer GW.

Antimicrob Agents Chemother. 1984 Oct;26(4):552-6.

38.

The effect of broad-spectrum antibiotics on warfarin excretion and metabolism in the rat.

Remmel RP, Elmer GW.

Res Commun Chem Pathol Pharmacol. 1981 Dec;34(3):503-14.

PMID:
7323446
39.

Influence of the intestinal microflora on the elimination of warfarin in the rat.

Remmel RP, Pohl LR, Elmer GW.

Drug Metab Dispos. 1981 Sep-Oct;9(5):410-4.

PMID:
6117438
40.

Influence of L-tyrosine phenol-lyase on the growth and metabolism of B16 melanoma.

Elmer GW, Linden C, Meadows GG.

Cancer Treat Rep. 1979 Jun;63(6):1055-62.

PMID:
466644
41.

Increased tyrosine phenol-lyase activity in mice following pyridoxal phosphate administration.

Elmer GW, Minor L, Meadows GG, Spackman DH, Riley V.

Cancer Res. 1978 Nov;38(11 Pt 1):3663-7.

42.

Albumin and alkaline phosphatase as factors involved in the regulation of tyrosine phenol-lyase activity.

Meadows GG, Elmer GW.

Res Commun Chem Pathol Pharmacol. 1978 Mar;19(3):513-27.

PMID:
653105
43.

New rapid determination of pyridoxal phosphate using tyrosine phenol-lyase.

Meadows GG, Boze L, Elmer GW.

J Pharm Sci. 1977 Oct;66(10):1503-5.

PMID:
925918
44.

Biliary excretion of warfarin metabolites and their metabolism by rat gut flora.

Powell ML, Pope B, Elmer GW, Trager WF.

Life Sci. 1977 Jan 1;20(1):171-7. No abstract available.

PMID:
13258
45.

Some biological properties and an in vivo evaluation of tyrosine phenol-lyase on growth of B-16 melanoma.

Meadows GG, DiGiovanni J, Minor L, Elmer GW.

Cancer Res. 1976 Jan;36(1):167-71.

46.
47.

Filamentous growth of Mucor rouxii under nitrogen.

Elmer GW, Nickerson WJ.

J Bacteriol. 1970 Feb;101(2):592-4.

Supplemental Content

Loading ...
Support Center